Investors Urged to Join Class Action Against Picard Medical Over Fraud Allegations

In recent news, Wolf Haldenstein Adler Freeman & Herz LLP has initiated a class action lawsuit against Picard Medical, Inc. (NYSE: PMI), specifically targeting shareholders who acquired the company's shares between September 2 and October 31, 2025. The firm emphasizes the urgency for these shareholders to step forward and join the action, with a looming deadline for lead plaintiff applications set for April 3, 2026.

Allegations of Misconduct

The complaint against Picard Medical paints a troubling picture, alleging that the company and its management enacted a fraudulent scheme that misled investors. Key points of contention include:
1. False and Misleading Statements: The lawsuit asserts that Picard provided inaccurate information regarding its financial status and future prospects, failing to disclose material facts that could affect investor decisions.
2. Fraudulent Stock Promotion: Central to the complaint is the allegation that Picard was involved in a deceptive stock promotion scheme utilizing social media to spread misinformation. This involved impersonating financial professionals and disseminating false information that artificially inflated the company’s stock prices.
3. Trading Activity Discrepancies: The lawsuit also highlights that insiders or affiliated parties allegedly utilized offshore accounts to facilitate the sale of shares during a misleading price inflation campaign, further implicating the company in unethical trading activities.

Furthermore, it is alleged that Picard Medical’s public disclosures neglected to mention harmful rumors or the artificial trading activity fueling stock price volatility. The combination of these factors has led to significant financial losses for shareholders.

Take Action

Wolf Haldenstein invites all investors who believe they may have been affected or have information pertinent to the investigation to reach out. The firm is dedicated to championing the rights of investors, boasting over 125 years of experience in securities litigation. They encourage prompt action, with lead plaintiff motions needing submission by the April deadline.

The firm provides multiple contact options for potential claimants:

- Phone: (800) 575-0735 or (212) 545-4774
- Email: [email protected]
- Contact: Gregory Stone, Director of Case and Financial Analysis

Why Wolf Haldenstein?

Established in 1888, Wolf Haldenstein has built a reputation as a staunch advocate for investors, unearthing facts and pursuing justice for those harmed by misrepresentation. Their extensive expertise in legal matters related to securities ensures that affected shareholders receive the representation they deserve.

In conclusion, shareholders of Picard Medical who have experienced losses are strongly advised to consider joining the class action suit before the April 3, 2026, deadline. With the support of experienced legal counsel, investors can take action to reclaim their losses and hold Picard accountable for its alleged misdeeds.